Is Sagimet Biosciences Inc. Series A Common Stock (SGMT) overvalued? · rev $2.0M
Sagimet Biosciences Inc. Series A Common Stock (SGMT) is a biotechnology company listed on NASDAQ.
This page asks whether Sagimet Biosciences Inc. Series A Common Stock (SGMT) looks expensive on cached numbers — not a short thesis.
Latest reported SGMT revenue for 2023-09-30 was $2.0M. Net income was -$6.4M. Revenue was up 0.0% from 2023-07-31 to 2023-09-30. SGMT currently screens at market cap $403.2M.
SGMT currently screens at market cap $403.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SGMT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SGMT stock page for the full model, not this heading.
Not investment advice.